[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"prospective-observational-study\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:prospective-observational-study":23},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100644426","prospective-observational-study-of-outcomes-after-gemcitabine-docetaxel-melphalan-and-carboplatin-with-autologous-stem-cell-transplantation-in-pediatric-relapsedrefractory-germ-cell-tumors-100644426",false,"NCT07662018","Prospective Observational Study of Outcomes After Gemcitabine, Docetaxel, Melphalan, and Carboplatin With Autologous Stem Cell Transplantation in Pediatric Relapsed\u002FRefractory Germ Cell Tumors","Inclusion Criteria\n\n* Male or female participants, greater than 1 month of age up to 21 years old. Neonates (birth to 1 month of age) will not be enrolled on this protocol.\n* Participants with relapsed\u002Frefractory seminomatous or nonseminomatous GCT who undergo an autologous stem cell transplantation (ASCT) with conditioning therapy including gemcitabine, docetaxel, melphalan, carboplatin (GemDMC) for germ cell tumors\n* As part of our analysis, we will also include participants aged 0-21 years old who have previously underwent ASCT with GemDMC\n* Participants who receive the following regimen:\n\nHigh dose chemotherapy (HDC) course #1:\n\nGemcitabine\u002FDocetaxel\u002FMelphalan\u002FCarboplatin D-6 Admission and start hydration D-5 Gemcitabine 1,500 mg\u002Fm2 IV Docetaxel 275 mg\u002Fm2 IV D-4 Gemcitabine 1,500 mg\u002Fm2 IV Melphalan 20 mg\u002Fm2 IV Carboplatin 250 mg\u002Fm2 IV D-3 Gemcitabine 1,500 mg\u002Fm2 IV Melphalan 20 mg\u002Fm2 IV Carboplatin 250 mg\u002Fm2 IV D-2 Gemcitabine 1,500 mg\u002Fm2 IV Melphalan 20 mg\u002Fm2 IV Carboplatin 250 mg\u002Fm2 IV D-1 Rest D0 Stem Cell infusion\n\nFollowed by HDC course #2 consisting of:\n\nHigh-dose course #2: Carboplatin\u002FEtoposide D-6 Admission and start hydration D-5 to -3 Etoposide 750 mg\u002Fm2 IV Carboplatin 700 mg\u002Fm2 IV D-2 Rest D-1 Rest D0 Stem Cell infusion\n\nExclusion Criteria\n\n* Participants who do not or did not receive GemDMC as part of the conditioning regimen for an ASCT are not eligible for this study","ALL","21 Years",{"count":18,"type":19},30,"ESTIMATED","OBSERVATIONAL","To collect information about treatment outcomes in pediatric and adolescent patients with relapsed\u002Frefractory germ cells tumors who receive GemDMC with an ASCT.",[23,24,25,26,27,28,29,30],"Prospective Observational Study","Gemcitabine","Docetaxel","Melphalan","Carboplatin","Stem Cell Transplantation","Pediatric Relapsed","Refractory Germ","RECRUITING","2026-06-17",{"date":34,"type":35},"2026-06-23","ACTUAL",{"date":37,"type":35},"2026-06-05",{"date":39,"type":19},"2033-12-31",{"name":41,"class":42},"M.D. Anderson Cancer Center","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":50,"minAge":4,"maxAge":4,"enrollmentInfo":51,"targetDuration":53,"studyType":20,"phases":4,"briefSummary":54,"conditions":55,"keywords":61,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":4},"100613664","a-prospective-validation-study-of-radiomics-in-the-differential-diagnosis-of-uterine-leiomyoma-and-uterine-sarcoma-100613664","NCT07269535","A Prospective Validation Study of Radiomics in the Differential Diagnosis of Uterine Leiomyoma and Uterine Sarcoma","1. Inclusion Criteria:\n\n   1.1 Patients clinically evaluated and radiologically examined (including MRI, particularly T2WI and DWI sequences) who are diagnosed with uterine leiomyoma or considered highly suspected of uterine sarcoma, in combination with preliminary pathological findings.\n\n   1.2 Patients scheduled for surgical treatment or those eligible for long-term standardized follow-up.\n\n   1.3 Patients who are able to understand the study procedures and voluntarily sign the written informed consent form.\n2. Exclusion Criteria:\n\n2.1 Patients with severe organic diseases or a previous confirmed diagnosis of other malignant uterine tumors.\n\n2.2 Patients unable to complete baseline examinations, unable to comply with long-term follow-up, or unwilling to provide written informed consent.","FEMALE",{"count":52,"type":19},500,"5 Years","In our previous study, based on the multi-center clinical big data collected from January 2012 to January 2025, we have completed the construction of a multimodal early warning model for the malignant transformation of uterine fibroids. The model was mainly based on T2WI and DWI sequences, and was trained and optimized by support vector machine (SVM) algorithm. In the retrospective study and internal validation, the model shows high sensitivity and specificity, which preliminarily proves that it has good application potential in identifying high-risk groups and predicting the risk of malignant transformation of uterine fibroids.\n\nHowever, there are still some limitations in retrospective studies and internal validation results, and its application value, universality and stability in real clinical environment have not been fully verified. Therefore, we plan to conduct a prospective validation study in consecutive patients enrolled after January 2025 to evaluate the clinical performance and generalization of the model in predicting the malignant tendency or risk of malignant transformation of uterine fibroids through practical application in the real population, and further analyze the operability in the actual diagnosis and treatment process and the potential value for patient management. This study will provide reliable evidence for early screening, follow-up management and individualized treatment of high-risk population, and has important clinical and public health significance for improving the early diagnosis rate, reducing the risk of malignant transformation and improving the prognosis of patients with uterine fibroids.",[56,57,58,59,23,60],"Uterine Fibroid","Uterine Sarcoma","AI (Artificial Intelligence)","Radiomic","MRI",[62,56,63,58,59,60],"prospective observational study","uterine sarcoma","NOT_YET_RECRUITING","2025-11-26",{"date":67,"type":35},"2025-12-08",{"date":69,"type":19},"2025-11-30",{"date":71,"type":19},"2050-01-01",{"name":73,"class":42},"Tongji Hospital"]